Generic Medicine Info
Indications and Dosage
Hypotensive states
Adult: As hydrochloride: 5 or 10 mg tid. Modified-release dosage form: 25 mg once or bid.
Preexisting hypertension; occlusive vascular disease; pheochromocytoma; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias.
Special Precautions
CV diseases; hyperthyroidism; diabetes mellitus; Parkinson's disease; elderly; pregnancy, lactation.
Adverse Reactions
CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of extremities; hypokalaemia; palpitations; tachycardia and arrhythmias. Gangrene.
Drug Interactions
Halogenated inhalation anaesthetics; β- or α-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce HTN and arrhythmia.
Lab Interference
Increase in bilirubin, catecholamines, glucose, uric acid.
Description: Etilefrine is a direct-acting sympathomimetic with β1-agonist and some α- and β2-agonist actions.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Etilefrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in